A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/17/2002	US20020151569 Peroxisome Proliferator Activated Receptors (PPARs) antagonists 4-oxo-5-thiazolidine acetamide derivatives
10/17/2002	US20020151565 Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
10/17/2002	US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002	US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002	US20020151557 CRF receptor antagonists and methods relating thereto
10/17/2002	US20020151555 Pyrimidine matrix metalloproteinase inhibitors
10/17/2002	US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002	US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002	US20020151546 HIV protease inhibitors based on amino acid derivatives
10/17/2002	US20020151531 Administering to a female of child bearing age over a period of 28 consecutive days a first phase of from 18 to 21 daily dosage units of a progestational agent, and a second phase of from 1 to 7 daily dosage units of an antiprogestin agent
10/17/2002	US20020151530 Administering to a woman, undergoing estrogen replacement therapy for treating homonal deficiences, continuously and uninterruptedly, a therapeutic effective amount of both estrogen and a non-aromatizing androgen in daily dosage
10/17/2002	US20020151503 Methods of cancer treatment using naaladase inhibitors
10/17/2002	US20020151501 Compounds having growth hormone releasing activity
10/17/2002	US20020151488 G-CSF analog compositions and methods
10/17/2002	US20020151483 C3b/C4b complement receptor-like molecules and uses thereof
10/17/2002	US20020151482 Administering to a bird or mammal a PRG-B polypeptide as an angiogenesis inhibitor; antitumor, -carcinogenic, -neoplastic and -arthritic agents; diabetic retinopathy; cancer of the lung, breast, or prostate gland; gene therapy
10/17/2002	US20020151481 MMP-2 propeptide for use as antiangiogenic or antitumor agent
10/17/2002	US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002	US20020151478 Fusion protein comprising a latency associated peptide and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent; gene therapy; genetic engineering; antiinflammatory agents
10/17/2002	US20020151475 Compounds and methods for modulating cell adhesion
10/17/2002	US20020151472 Trefoil factor (TFF) peptides (tricyclic peptides, e.g., TFF2 peptides), for increasing the viscosity of mucus layers; used for treating damaged or abnormal mucus layers, e.g. in the gastrointestinal tract, respiratory/urogential systems, eyes
10/17/2002	US20020151022 Kinase capable of site-specific phosphorylation of IkappaBalpha
10/17/2002	US20020151021 Stimulus-inducible protein kinase complex and methods of use therefor
10/17/2002	US20020151015 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/17/2002	US20020151011 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
10/17/2002	US20020150993 Nucleotide sequences coding polypeptide for use in the treament of apoptosis, inflammatory or autoimmune diseases
10/17/2002	US20020150992 Nucleotide sequences coding polypeptide for us ein the treatment of immunological disorders
10/17/2002	US20020150986 Extracellular matrix signalling molecules
10/17/2002	US20020150984 Peptides for activation and inhibition of deltaPKC
10/17/2002	US20020150981 Methods for producing highly phosphorylated lysosomal hydrolases
10/17/2002	US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	US20020150601 Topical applying
10/17/2002	US20020150577 Transforming growth factor; transgenic animal; increas ratios of muscle mass
10/17/2002	US20020150574 Cancer diagnosis, therapy; Dna vaccine
10/17/2002	US20020150570 Anti-CCR2 antibodies and methods of use therefor
10/17/2002	US20020150567 Novel grb2 associating polypeptides and nucleic acids encoding therefor
10/17/2002	US20020150562 Viral preparations, vectors, immunogens, and vaccines
10/17/2002	US20020150555 Interleukins; osteoporosis therapy
10/17/2002	DE10201458A1 New proteins involved in isoprenoid biosynthesis, useful in screening for inhibitors, also new intermediates, potential therapeutic agents, nucleic acids and antibodies
10/17/2002	DE10164711A1 Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen Use of sugar phosphates, sugar phosphate analogs, amino acids and / or amino acid analogs to modulate the glycolytic enzyme complex, the malate aspartate shuttle and / or the transaminases
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002	DE10118306A1 Composition for intranasal administration of imidazo-triazinone derivative cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10118305A1 Composition for intranasal administration of cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10117184A1 Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen Substituted imidazol [1,2-a] pyridin-3-yl-amide, and amine compounds of
10/17/2002	CA2719162A1 Methods of treating acne
10/17/2002	CA2443372A1 Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
10/17/2002	CA2443334A1 Protein modification and maintenance molecules
10/17/2002	CA2443330A1 Anti-osteopontin antibody and use thereof
10/17/2002	CA2443275A1 Improved gene expression
10/17/2002	CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	CA2443085A1 Somatostatin agonists
10/17/2002	CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	CA2443042A1 Novel use of arylethene sulfonamide derivatives
10/17/2002	CA2442996A1 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	CA2442991A1 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	CA2442986A1 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments
10/17/2002	CA2442904A1 Benzamidine derivative
10/17/2002	CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442695A1 Indolinones substituted in the 6-position, the preparation thereof and their use as medicaments
10/17/2002	CA2442605A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442530A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442315A1 Glycosaminoglycan/collagen complexes and use thereof
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441941A1 Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	CA2429376A1 Mitogenic oxygenase regulators
10/16/2002	WO2001079201A1 Process for preparation of sulfonamide derivatives and crystals thereof
10/16/2002	WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002	EP1249451A2 Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
10/16/2002	EP1249450A1 Benzimidazole derivatives
10/16/2002	EP1249245A1 Remedies and/or preventives for nervous system disorders
10/16/2002	EP1249238A2 Topical pharmaceutical composition comprising betanechol
10/16/2002	EP1249237A1 Skin external agents and drugs
10/16/2002	EP1249233A1 Npyy5 antagonists
10/16/2002	EP1248858A1 Antisense modulation of caspase 8 expression
10/16/2002	EP1248852A2 Method of assessing the viability of a cell
10/16/2002	EP1248847A1 Irak-4: compositions and methods of use
10/16/2002	EP1248846A2 Human kinase protein and polynucleotides encoding the same
10/16/2002	EP1248837A2 Angiotensin converting enzyme homolog and its use
10/16/2002	EP1248836A2 Hybrid cells obtainable from antigen presenting cells
10/16/2002	EP1248835A2 Genetically modified fibroblast cell
10/16/2002	EP1248833A1 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition
10/16/2002	EP1248803A2 Nogo receptor-mediated blockade of axonal growth
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248791A1 Antisense modulation of caspase 3 expression
10/16/2002	EP1248787A2 Novel subtituted pyrazolo[4, 3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
10/16/2002	EP1248784A1 Condensed azepines as vasopressin agonists
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248779A2 Glycosidase ihhibitors and preparation thereof
10/16/2002	EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
10/16/2002	EP1248770A1 1,3,4-substituted piperidine analogs and uses thereof in treating addictions
10/16/2002	EP1248769A2 Carbazole derivatives as inhibitors of spla2
10/16/2002	EP1248763A2 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors
10/16/2002	EP1248651A1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
10/16/2002	EP1248643A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

1 ... 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 ... 1564